

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 April 2024 (04.04.2024)



(10) International Publication Number
WO 2024/069592 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) A61K 31/551 (2006.01)
A61K 31/55 (2006.01) A61K 31/4439 (2006.01)
A61K 31/435 (2006.01) A61K 31/4545 (2006.01)
A61K 31/443 (2006.01) A61K 31/4985 (2006.01)
A61K 31/444 (2006.01) A61K 31/5377 (2006.01)
A61K 31/496 (2006.01) A61K 31/5386 (2006.01)
A61K 31/497 (2006.01) A61K 51/04 (2006.01)
A61K 31/499 (2006.01) A61P 35/00 (2006.01)
A61K 31/501 (2006.01) C07D 417/12 (2006.01)
A61K 31/502 (2006.01) C07D 487/04 (2006.01)
A61K 31/506 (2006.01) C07D 491/048 (2006.01)
A61K 31/541 (2006.01) C07D 491/107 (2006.01)

(21) International Application Number:

PCT/IB2023/059814

(22) International Filing Date:

29 September 2023 (29.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CA2022/051446

29 September 2022 (29.09.2022) CA
63/455,612 30 March 2023 (30.03.2023) US

(71) Applicant: **REPAIRE THERAPEUTICS INC.** [CA/CA];
7210 Frederick-Banting, Suite 100, St-Laurent, Québec
H4S 2A1 (CA).

(72) Inventors: **LIU, Bingcan**; 204 St. Aubin, Montréal,
Québec H4M 2H9 (CA). **PERRYMAN, Alexander**;
128 Boul Hymus, Apt. 501, Pointe-Claire, Québec H9R
1E8 (CA). **MOCHIRIAN, Philippe**; 7071 Rue Saint-
André, Montréal, Québec H2S 2L3 (CA). **GALLANT,**
Michel; 18533 Lagrange, Pierrefonds, Québec H9K 1R4
(CA). **BENDAHAN, David**; 101-6635 Chemin Mack-
le, Cote Saint Luc, Québec H4W 2Z7 (CA). **SUR-**
PRENANT, Simon; 1087, rue Chablis, Boisbriand, Québec
J7G 2Y9 (CA). **SZYCHOWSKI, Janek**; 5888, av-
enue Chateaubriand, Montréal, Québec H2S 2N2 (CA).

DIETRICH, Evelyne; 337 avenue Bazin, Laval, Québec
H7N 4R6 (CA). **SOW, Boubacar**; 201-150, rue des
Aubépines, Vaudreuil-Dorion, Québec J7V 0Y3 (CA).
BUBENIK, Monica; 5060 Pharand, Laval, Québec H2X
0C6 (CA). **MORRIS, Stephen**; 7171 Frederick-Banting,
Building 2, St-Laurent, Québec H4S 1Z9 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE

(54) Title: N-(5-SUBSTITUTED-[(L,3,4-THIADIAZOLYL) OR (L,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COM-
POUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF
THEIR USE



(I)

(57) Abstract: The present application discloses specific compounds of Formula (I) and their use in therapy, in particular, their use as Polymerase Theta (Polθ) inhibitors for the treatment of cancer. The application further discloses the use of a combination comprising a compound of Formula (I) and a radiotherapy or a radioligand in therapy, in particular, the use of specific compounds of Formula (I) as a Polymerase Theta (Polθ) inhibitor in combination with a radiotherapy or a radioligand for the treatment of cancer. (Formula I)

WO 2024/069592 A1